Pozen Inc. is beefing up its balance sheet by trading royalties for marketed migraine drug Treximet (sumatriptan/naproxen sodium) in exchange for $75 million in cash, a move the Chapel Hill, N.C.-based firm said will put it on solid financial footing as it starts partnering negotiations for PA32540, a gastrointestinal-friendly aspirin candidate in late-stage development.